Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Information on natalizumab (marketed as Tysabri)
Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
CD4 cell response to interval therapy with natalizumab.
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study.
Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset.
Biochemical Markers of Autoimmune Diseases of the Nervous System.
Multiple sclerosis treatment: current best practice.
Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature.
Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study.
Influence of pregnancy on neuromyelitis optica spectrum disorder.
[Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a german high-volume clinic].
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter.
Teva to initiate third Phase III trial of oral laquinimod for the treatment of relapsing remitting multiple sclerosis
Optic nerve disease and axon pathophysiology.
Confronting the diagnosis of multiple sclerosis: a qualitative study of patient experiences.
Biologics at Novartis
Characterization of human platelet binding of recombinant T cell receptor ligand.
Successful desensitization to natalizumab in a skin test--positive patient: a case report.
The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis.
Rush University Medical Center Sells AMPYRA® Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.

Pages